| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Agrimol B is a naturally occurring polyphenol isolated from Agrimonia pilosa Ledeb with anti-adipogenic, anticancer activity and antibacterial activity. Suppressing adipogenesis via inducing SIRT1 translocation and expression (SIRT1 activator), and reducing PPARγ expression.
| ln Vitro |
Using an IC50 of 3.35 ± 0.32 μM, Agrimol B inhibits adipogenesis in the early phases of obesity in a dose-dependent manner[1]. Agrimol B inhibits the growth of PC-3 and A549 cells, with GI50 (50% growth inhibition) values of 29 and 23, respectively. Agrimol B induces SIRT1 (silent information regulator 2 homolog 1) translocation and expression in 3T3-L1 adipocytes [1]. GI75 values are 49 and 50 μM, GI90 values are 63 and 76 μM, and 19 μM, respectively [2]. In both cell lines, Agrimol B (0-76 μM) added A G0 cells quantitatively reduces c-MYC and SKP2 (S-phase state-associated protein 2) over a 3-day period [2]. SPT16 (Suppressor of Ty Homolog-16), p27 (cyclin-coupling protein 1B), and SSRP1 (structural bridge recognition protein 1) [2].
|
|---|---|
| ln Vivo |
Agrimol B (10 mg/kg, mouse, every day) restricts the growth of xenografts [2].
|
| Cell Assay |
Cell Cycle Analysis[2]
Cell Types: PC-3 and A549 Cell Tested Concentrations: 29 and 63 μM (PC-3), 19 and 76 μM (A549) Incubation Duration: 10 minutes Experimental Results: Number of G0 phase cells in both cell lines Increased in a dose-dependent manner. The percentage of Ki-67-positive cells diminished and the p27-positive cell population increased in PC-3 and A549 cells. Western Blot Analysis[2] Cell Types: PC-3 and A549 Cell Tested Concentrations: 0, 29, 49, 63 μM (PC-3); 0, 19, 50 and 76 μM (A549) Incubation Duration: 3 days Experimental Results: Two c-MYC and SKP2 were diminished, p27 was increased, SPT16 and SSRP1 were down-regulated in A549 cells, and CRM1 in the two cell lines was not affected. Immunofluorescence[1] Cell Types: 3T3-L1 Preadipocyte Tested Concentrations: 0, 3, 10 μM Incubation Duration: 6 days Experimental Results: Dramatically increased nuclear positive rate of SIRT1; Markedly increased SIRT1 expression at 10 μM, the effect vanished at 3 μM. Down-regulated PPARγ and C/EBPα (CCAAT/enhancer-binding protein α) expression; Dramatically diminished FAS (fatty acid synthesis), UCP-1 (uncoupling protein-1), and apoE (apolipoprotein E) expression at 10 μM. |
| Animal Protocol |
Animal/Disease Models: BALB/c nude mice (6 weeks old, male, injected with PC-3) cells were injected subcutaneously (sc) (sc) in 0.2 mL PBS) [2]
Doses: 10 mg/kg Route of Administration: daily after 15 days of cancer cell implantation Oral Experimental Results: Inhibition of tumor growth in a mouse model of human prostate cancer, with reduction in tumor volume on day 31 and day 32. |
| References |
|
| Molecular Formula |
C37H46O12
|
|---|---|
| Molecular Weight |
682.7540
|
| Exact Mass |
682.298
|
| CAS # |
55576-66-4
|
| PubChem CID |
194000
|
| Appearance |
White to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
922.6±65.0 °C at 760 mmHg
|
| Flash Point |
284.4±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.612
|
| LogP |
10.45
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
49
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCC(=O)C1=C(C(=C(C(=C1O)CC2=C(C(=C(C(=C2O)C(=O)[C@@H](C)CC)O)CC3=C(C(=C(C(=C3O)C)OC)C(=O)CCC)O)O)O)C)OC
|
| InChi Key |
BVLHMPZMQVWDGX-INIZCTEOSA-N
|
| InChi Code |
InChI=1S/C37H46O12/c1-9-12-23(38)25-32(44)19(29(41)17(5)36(25)48-7)14-21-31(43)22(35(47)27(34(21)46)28(40)16(4)11-3)15-20-30(42)18(6)37(49-8)26(33(20)45)24(39)13-10-2/h16,41-47H,9-15H2,1-8H3/t16-/m0/s1
|
| Chemical Name |
(2S)-1-[3,5-bis[(3-butanoyl-2,6-dihydroxy-4-methoxy-5-methylphenyl)methyl]-2,4,6-trihydroxyphenyl]-2-methylbutan-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5.56 mg/mL (~8.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.43 mg/mL (2.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4647 mL | 7.3233 mL | 14.6466 mL | |
| 5 mM | 0.2929 mL | 1.4647 mL | 2.9293 mL | |
| 10 mM | 0.1465 mL | 0.7323 mL | 1.4647 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
